Omeros drops as transplant therapy faces EU hurdle
Seeking Alpha ·
Shares of Omeros ( OMER ) fell ~25% in the premarket on Friday after an expert panel of the EU drug regulator, the European Medicines Agency, declined to endorse the company's transplant therapy narsoplimab. In a statement, the Seattle, Washington-based biotech said that the
DYAX Investor Sentiment
Bullish (Long) 41% · Bearish (Short) 59%
445 participants
Related News
- Medicare GLP-1 Bridge: What to expect
- Apple can't shield buyers from Al's memory crunch anymore
- Big Tech’s Quiet Diversification Out of Taiwan Is the Ultimate Catalyst for Intel’s Turnaround
- Oppenheimer’s case for SpaceX: Communications is the largest market to go after
- Interactive Brokers Is a Sneaky Way to Profit From High Interest Rates
- Returns?! Many enterprises lack benchmarks for measuring success of AI: Wedbush